InvestorsObserver is giving CTI BioPharma Corp (CTIC) an Analyst Rating Rank of 59, meaning CTIC is ranked higher by analysts than 59% of stocks. The average price target for CTIC is $6.9 and analyst’s rate the stock as a Strong Buy
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With CTI BioPharma Corp Stock Today?
CTI BioPharma Corp (CTIC) stock is trading at $3.35 as of 11:00 AM on Monday, Mar 22, a rise of $0.15, or 4.69% from the previous closing price of $3.20. Volume today is above average. So far 3,538,350 shares have traded compared to average volume of 595,550 shares. The stock has traded between $3.14 and $4.13 so far today.
Click Here to get the full report on CTI BioPharma Corp (CTIC) Stock.
